How Do We Treat Patients With Advanced Hepatocellular… : Oncology Times
An abstract is unavailable.
Related Articles
The Novel Bispecific Antibody Ivonescimab May be Poised to Change the SOC in NSCLC
Jonathan Wesley Riess, MD, MS, details the potential for ivonescimab in NSCLC after improving PFS vs pembrolizumab in the HARMONi-2 trial.
New colorectal cancer screening strategies must advance the standard of care – The Cancer Letter
Colorectal cancer is the second leading cause of cancer-related death in the United States. Accurate and early detection of CRC and precancerous lesions is critical…
New Developments in CAR T Treatments Webinar Infographic Series
The following infographics are based on New Developments in CAR T Treatments Webinar Series, which aired on Tuesday, September 10, at 12 p.m. CDT and featured…
Pediatric cancer research cut from spending legislation at last minute Republicans quietly removed hard-won pediatric cancer bills – The Cancer Letter
On Saturday, Dec. 21, Congress passed a new spending package, narrowly averting a government shutdown. To access this subscriber-only content please log in or subscribe.If your…
Spinal Injuries and Spine Care in the U.S. Military Health… : Spine
injuries in combat and non-combat settings as reported in the literature over the last 15 to 20 years. Background. Military service places servicemembers under substantial…
As fire encroached, City of Hope prepared to evacuate its Duarte campus – The Cancer Letter
On Jan. 7, a bit after 6 p.m., Ravi Salgia was at his Eaton Canyon home, at the edge of Angeles National Forest. To access…
The current landscape of frontline large B-cell lymphoma trials
Since the addition of rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), major advances in first-line therapy of large B-cell
Combined ODAC documents
Combined Food and Drug Administration and Sponsor Oncologic Drugs Advisory Committee Briefing Document
Exploring Add-on Therapy With CK0804 for Patients With Myelofibrosis With Suboptimal Response to Ruxolitinib
According to data presented at the 66th ASH Annual Meeting by Lucia Masarova, MD, CXCR4-enriched T regulatory cell therapy (CK0804) as an addition to ruxolitinib…
Post-Operative Nivolumab Significantly Improves DFS in Head and Neck Cancer
Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, meeting the primary end point of the phase 3 NIVOPOSTOP trial.
